Macrophage-Biomimetic Nanoparticles Ameliorate Ulcerative Colitis through Reducing Inflammatory Factors Expression.
Macrophage-Biomimetic Nanoparticles Ameliorate Ulcerative Colitis through Reducing Inflammatory Factors Expression.
复制标题
巨噬细胞仿生纳米颗粒通过减少炎症因子表达改善溃疡性结肠炎
DOI：
10.1159/000519363
复制
发表时间：
2022
影响因子：
5.3
通讯作者：
Ma, Jian
中科院分区：
文献类型：
--
作者：
Li, Zhengshuo;Zhang, Xiaoyue;Liu, Can;Peng, Qiu;Wu, Yangge;Wen, Yuqing;Zheng, Run;Yan, Qun;Ma, Jian
背景和目的：炎症介质S100 A9在溃疡性结肠炎中显著升高，并与疾病严重程度相关。S100 A9是治疗结肠炎的潜在靶向分子，但迄今为止，还没有有效的靶向方法。本研究的目的是开发一种安全有效的靶向S100 A9的纳米给药系统，并评价其在溃疡性结肠炎小鼠模型中的治疗效果。研究方法：我们设计了一种口服纳米给药系统，使用聚（乳酸-乙醇酸）（PLGA）负载S100 A9抑制剂tasquinimod合成PLGA-TAS纳米粒。使用TLR 4过表达巨噬细胞膜（MLA）包裹纳米颗粒以制备MM-PLGA-TAS，这允许纳米颗粒获得特异性富集结肠炎区域的能力。结果如下：MM-PLGA-TAS在体外可被炎性表型RAW264.7细胞内吞，并在体内可有效富集于炎症小鼠结肠炎组织中。使用化学诱导的溃疡性结肠炎小鼠模型评价口服MM-PLGA-TAS的治疗效果。MM-PLGA-TAS可显著缓解溃疡性结肠炎的症状，机械上，MM-PLGA-TAS通过减少结肠炎区域的S100 a9和其他细胞因子而达到免疫调节和抑制作用。结论：我们描述了一种方便的口服靶向结肠炎给药系统，可治疗溃疡性结肠炎小鼠的疾病。该系统大大增加了药物在发炎的结肠组织中的积累，降低了全身暴露的风险，是一种有前途的治疗溃疡性结肠炎的方法。
Background and Aims: Inflammatory mediator S100A9 is dramatically elevated in ulcerative colitis and correlates with disease severity. S100A9 is a potential molecule to target for the treatment of colitis, but to date, there is no effective targeting method. The aim of this study was to develop a safe and effective nano-delivery system targeting S100A9 and to evaluate its therapeutic efficacy in ulcerative colitis mouse model. Methods: We designed an oral nano-delivery system using poly (lactic acid-glycolic acid) (PLGA)-loaded S100A9 inhibitor tasquinimod to synthesize PLGA-TAS nanoparticles. TLR4-overexpressing macrophage membranes (MMs) were used to wrap the nanoparticles to make MM-PLGA-TAS, which allowed the nanoparticles to acquire the ability to specifically enrich the colitis region. Results: MM-PLGA-TAS was endocytosed by inflammatory phenotype RAW264.7 cells in vitro and can efficiently enrich in inflamed mouse colitis tissue in vivo. A chemically induced ulcerative colitis mouse model was used to evaluate the therapeutic effect of oral MM-PLGA-TAS. MM-PLGA-TAS significantly alleviated the symptoms of ulcerative colitis, and mechanically, MM-PLGA-TAS achieved immunomodulatory and suppressive effects by reducing S100a9 and other cytokines in the colitis region. Conclusion: We describe a convenient, orally targeted colitis drug delivery system that cures the disease in ulcerative colitis mice. This system substantially increases drug accumulation in inflamed colonic tissue, reduces the risk of systemic exposure, and is a promising therapeutic approach against ulcerative colitis.
登录
查看更多内容
仿生聚合物磁性纳米载体极化肿瘤相关巨噬细胞，用于增强免疫治疗
影响因子：
13.3
作者：
Liu, Lingqiao;Wang, Yi;Zhou, Shaobing
通讯作者：
Zhou, Shaobing
DNA甲基化和基因表达谱的综合分析将S100A9鉴定为溃疡性结肠炎的潜在生物标志物。
影响因子：
4
作者：
Su S;Kong W;Zhang J;Wang X;Guo H
通讯作者：
Guo H
影响因子：
24.5
作者：
Hoivik, Marte Lie;Moum, Bjorn;Bernklev, Tomm
通讯作者：
Bernklev, Tomm
抗 S100a9 抗体在小鼠体内抑制结肠炎和结肠炎相关结肠癌
影响因子：
7.3
作者：
Zhang X;Wei L;Wang J;Qin Z;Wang J;Lu Y;Zheng X;Peng Q;Ye Q;Ai F;Liu P;Wang S;Li G;Shen S;Ma J
通讯作者：
Ma J
巨噬细胞仿生纳米颗粒通过靶向药物疗法和促炎细胞因子的隔离治疗动脉粥样硬化
影响因子：
16.6
作者：
Gao, Cheng;Huang, Qiaoxian;Wang, Ruibing
通讯作者：
Wang, Ruibing